RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles
RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles
复制标题
DOI：
10.4161/cbt.8.7.7790
复制
发表时间：
2009-04-01
影响因子：
3.6
通讯作者：
Ni, Quanxing
中科院分区：
文献类型：
--
作者：
Luo, Guopei;Jin, Chen;Ni, Quanxing
甲基CpG结合域蛋白1(MBD1)是一种转录调控因子，能与肿瘤抑制基因的甲基化CpG岛结合并抑制其转录。在以前的研究中，我们发现MBD1在胰腺癌细胞株和胰腺癌组织中高表达，可能在胰腺癌的发生发展中起重要作用。在本研究中，我们将MBD1的siRNA序列导入PLGA：泊洛沙姆载体中，以检测该化合物对BxPC-3人胰腺癌细胞的治疗作用。我们发现MBD1siRNA可以成功地导入肿瘤细胞，并且MBD1siRNA纳米颗粒化合物具有抑制细胞生长和诱导细胞凋亡的作用。MBD1纳米粒子是一种很有前途的体外胰腺癌基因治疗候选药物。
Methyl-CpG binding domain protein 1 (MBD1) is a transcriptional regulator that binds methylated CpG islands of tumor suppressor genes and represses their transcription. In a former study, we found high expression of MBD1 in pancreatic cancer cell lines and tissues which may play an important role in the development of pancreatic cancer. In the present study, we incorporated the siRNA sequence of MBD1 plasmid into a PLGA: Poloxamer carrier to test the therapeutic effect of this compound on BxPC-3 human pancreatic cancer cells. We found that an MBD1 siRNA plasmid can be successfully transfected into tumor cells and the MBD1 nanoparticle compound can inhibit cell growth and induce apoptosis. The MBD1 nanoparticle is a promising candidate for gene therapy of pancreatic cancer in vitro.